Cikkek nyilvánosan hozzáférhető megbízással - Charles RudinTovábbi információ
Sehol sem hozzáférhető: 7
Áttekintés
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
A Drilon, N Rekhtman, M Arcila, L Wang, A Ni, M Albano, ...
The Lancet Oncology 17 (12), 1653-1660, 2016
Megbízások: US National Institutes of Health
Áttekintés
Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases
FP Vendetti, CM Rudin
Expert opinion on biological therapy 13 (9), 1273-1285, 2013
Megbízások: US National Institutes of Health
Áttekintés
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
K Kawasaki, N Rekhtman, Á Quintanal-Villalonga, CM Rudin
Nature reviews Clinical oncology 20 (1), 16-32, 2023
Megbízások: US National Institutes of Health
Áttekintés
Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and …
SR Yang, E Gedvilaite, R Ptashkin, J Chang, J Ziegler, DA Mata, ...
Journal of Thoracic Oncology 19 (3), 409-424, 2024
Megbízások: US National Institutes of Health
Áttekintés
TGF-β and RAS jointly unmask primed enhancers to drive metastasis
JH Lee, FJ Sánchez-Rivera, L He, H Basnet, FX Chen, E Spina, L Li, ...
Cell 187 (22), 6182-6199. e29, 2024
Megbízások: Howard Hughes Medical Institute
Áttekintés
CRACD loss promotes small cell lung cancer tumorigenesis via EZH2-mediated immune evasion.
S Zhang, KB Kim, Y Huang, DW Kim, B Kim, KP Ko, G Zou, J Zhang, S Jun, ...
Biorxiv: the Preprint Server for Biology, 2023
Megbízások: US National Institutes of Health, Cancer Prevention Research Institute of …
Áttekintés
Breathing room–focusing on the ‘other’lung cancer
CM Rudin
Nature Cancer 4 (9), 1212-1213, 2023
Megbízások: US National Institutes of Health
Valahol hozzáférhető: 301
Áttekintés
Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
Megbízások: US National Institutes of Health
Áttekintés
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
Megbízások: US National Institutes of Health
Áttekintés
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ...
Jama 311 (19), 1998-2006, 2014
Megbízások: US National Institutes of Health
Áttekintés
Efficacy and safety of vismodegib in advanced basal-cell carcinoma
A Sekulic, MR Migden, AE Oro, L Dirix, KD Lewis, JD Hainsworth, ...
New England Journal of Medicine 366 (23), 2171-2179, 2012
Megbízások: US National Institutes of Health
Áttekintés
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
Megbízások: US National Institutes of Health, V Foundation, USA
Áttekintés
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled …
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of clinical oncology 36 (7), 633-641, 2018
Megbízások: US National Institutes of Health
Áttekintés
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
CM Rudin, CL Hann, J Laterra, RL Yauch, CA Callahan, L Fu, T Holcomb, ...
New England Journal of Medicine 361 (12), 1173-1178, 2009
Megbízások: US National Institutes of Health
Áttekintés
Small-cell lung cancer
CM Rudin, E Brambilla, C Faivre-Finn, J Sage
Nature Reviews Disease Primers 7 (1), 3, 2021
Megbízások: US National Institutes of Health, National Institute for Health Research, UK
Áttekintés
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709-717, 2017
Megbízások: US National Institutes of Health
Áttekintés
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
CM Rudin, S Durinck, EW Stawiski, JT Poirier, Z Modrusan, DS Shames, ...
Nature genetics 44 (10), 1111-1116, 2012
Megbízások: US National Institutes of Health
Áttekintés
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ...
Nature Reviews Cancer 19 (5), 289-297, 2019
Megbízások: US National Institutes of Health, US Department of Veterans Affairs, Cancer …
Áttekintés
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma
RL Yauch, GJP Dijkgraaf, B Alicke, T Januario, CP Ahn, T Holcomb, ...
Science 326 (5952), 572-574, 2009
Megbízások: US National Institutes of Health
Áttekintés
Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ...
Cancer cell 33 (5), 843-852. e4, 2018
Megbízások: US National Institutes of Health, Cancer Research UK, Wellcome Trust
A publikációs és a finanszírozási adatokat számítógépes program határozza meg, automatikusan.